Patents Examined by Mark Halvorson
  • Patent number: 10544215
    Abstract: The invention provides antibody-drug conjugates comprising an antibody conjugated to a 1-(chloromethyl)-2,3-dihydro-1H-benzo[e]indole (CBI) dimer drug moiety via a linker, and methods of using the antibody-drug conjugates.
    Type: Grant
    Filed: June 14, 2016
    Date of Patent: January 28, 2020
    Assignee: Genentech, Inc.
    Inventors: John A. Flygare, Thomas H. Pillow, Brian Safina, Vishal Verma, BinQing Wei, William Denny, Anna Giddens, Ho Lee, Guo-Liang Lu, Christian Miller, Gordon Rewcastle, Moana Tercel, Muriel Bonnet
  • Patent number: 10545075
    Abstract: Methods and compositions are provided for preparing a biological specimen for microscopic analysis. These methods find many uses, for example in medicine and research, e.g., to diagnose or monitor disease or graft transplantation, to study healthy or diseased tissue, to screen candidate agents for toxicity and efficacy in disease modification. Also provided are reagents, devices, kits and systems thereof that find use in practicing the subject methods.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: January 28, 2020
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Karl A. Deisseroth, Kwanghun Chung
  • Patent number: 10539566
    Abstract: Methods for diagnosing the presence of prostate cancer in a subject are provided, such methods including the detection of levels of variety of biomarkers diagnostic of prostate cancer, including filamin A alone, or in combination with one or more additional biomarkers of prostate cancer, including, PSA, keratin 4, keratin 7, keratin 8, keratin 15, keratin 18, keratin 19, tubulin-beta 3, filamin B, and LY9. Additionally, age can be used as a predictor variable. The invention also provides methods of treating prostate cancer which rely on diagnostic information obtained based on the detection of biomarkers of prostate cancer, including filamin A alone, or in combination with one or more additional biomarkers of prostate cancer, including, PSA, keratin 4, keratin 7, keratin 8, keratin 15, keratin 18, keratin 19, tubulin-beta 3, filamin B, LY9, and/or age. Compositions in the form of kits and panels of reagents for detecting the biomarkers of the invention are also provided.
    Type: Grant
    Filed: December 8, 2015
    Date of Patent: January 21, 2020
    Assignee: Berg LLC
    Inventors: Niven Rajin Narain, Vivek K. Vishnudas, Rangaprasad Sarangarajan, Viatcheslav R. Akmaev
  • Patent number: 10537644
    Abstract: The present invention provides novel and advantageous compositions having a linker capable of covalently coupling one or more free thiols of an antibody. Specifically, provided herein are the molecular structures, synthetic pathways, coupling mechanisms, and applications thereof as used in an antibody-drug conjugate (ADC).
    Type: Grant
    Filed: August 15, 2016
    Date of Patent: January 21, 2020
    Assignee: RC BIOTECHNOLOGIES, INC.
    Inventors: Chang Jiang Huang, Jianmin Fang, Hui Ye, Lezhi Zhang
  • Patent number: 10533058
    Abstract: This invention relates to peptidomimetic linkers and anti-body drug conjugates thereof, pharmaceutical compositions containing them, and to their use in therapy for the prevention treatment of cancer.
    Type: Grant
    Filed: December 16, 2014
    Date of Patent: January 14, 2020
    Assignees: Genentech Inc., Medimmune Limited
    Inventors: John Flygare, Janet Gunzner-Toste, Thomas Pillow, Brian Safina, Vishal Verma, Binqing Wei, Guiling Zhao, Leanna Staben, Philip Wilson Howard, Luke Masterson
  • Patent number: 10526607
    Abstract: The invention relates to a novel cell derived from the human body, where said cell comprises a Clever-1 receptor; to a method for affecting the immune system of an individual and for treatment of diseases or conditions related to the function of the immune system and to methods for screening of cancer patients that may respond to an anti-Clever-1 therapy or for diagnosing of a pregnancy complication or for estimating the risk of such complication in a pregnant woman.
    Type: Grant
    Filed: March 25, 2014
    Date of Patent: January 7, 2020
    Assignee: FARON PHARMACEUTICALS OY
    Inventors: Sirpa Jalkanen, Marko Salmi, Markku Jalkanen
  • Patent number: 10527623
    Abstract: The present invention relates to antigen recognizing constructs against a tumor associated antigen (TAA) derived from the target protein DDB1 and CUL4 associated factor 4-like 2 (DCAF4L2). The invention in particular provides novel T cell receptor (TCR) based molecules which are selective and specific for the TAA of the invention. The TCR of the invention, and TAA binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of TAA expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.
    Type: Grant
    Filed: December 7, 2017
    Date of Patent: January 7, 2020
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Leonie Alten, Sebastian Bunk, Dominik Maurer, Claudia Wagner
  • Patent number: 10526416
    Abstract: An isolated polypeptide is provided. The isolated polypeptide comprising an antigen recognition domain specifically binding human HER-3 with a KD value of 10 nM or lower, wherein the polypeptide inhibits neuregulin (NRG) binding to the human HER3 and NRG-induced cancer cell migration and proliferation. Additionally clones NG83 and NG140 are provided which bind human HER-3 with a KD value of 10 nM or lower.
    Type: Grant
    Filed: September 8, 2015
    Date of Patent: January 7, 2020
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Yosef Yarden, Nadège Gaborit, Moshit Lindzen
  • Patent number: 10517861
    Abstract: Biomarkers are provided that predict whether a subject having endometrial cancer will or will not respond to a therapy comprising lenvatinib or a pharmaceutically acceptable salt thereof (e.g., lenvatinib mesylate). The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for and treating a subject having, suspected of having, or at risk of developing an endometrial cancer.
    Type: Grant
    Filed: May 12, 2014
    Date of Patent: December 31, 2019
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Yasuhiro Funahashi, Tadashi Kadowaki, Pallavi Sachdev
  • Patent number: 10519131
    Abstract: Benzazepine compounds, conjugates, and pharmaceutical compositions for use in the treatment of disease, such as cancer, are disclosed herein. The disclosed benzazepine compounds are useful, among other things, in the treating of cancer and modulating TLR8. Additionally, benzazepine compounds incorporated into a conjugate with an antibody construct are described herein.
    Type: Grant
    Filed: May 7, 2018
    Date of Patent: December 31, 2019
    Assignee: SILVERBACK THERAPEUTICS, INC.
    Inventors: Craig Alan Coburn, Peter Robert Baum, Sean Wesley Smith
  • Patent number: 10519238
    Abstract: The present invention is based, in part, on the discovery of anti-galectm-1 (Gal 1.) monodonai antibodies useful for diagnostic and prognostic applications, as well as immunoglobulins, polypeptides, and nucleic acids thereof.
    Type: Grant
    Filed: July 23, 2014
    Date of Patent: December 31, 2019
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Margaret A. Shipp, Jing Ouyang, Scott J. Rodig
  • Patent number: 10520512
    Abstract: Subject matter of the present invention is a method for predicting the risk of a subject for contracting diabetes mellitus and/or metabolic syndrome or for diagnosing metabolic syndrome in a subject wherein said subject is non-diabetic, comprising the following steps determining the level of pro-neurotensin or fragments thereof of at least 5 amino acids in a bodily fluid obtained from said subject; and correlating said level of pro-neurotensin or fragments thereof with the risk of said subject for contracting diabetes mellitus and/or metabolic syndrome, wherein an elevated level is predictive for an enhanced risk of getting diabetes mellitus and/or metabolic syndrome, or wherein an elevated level correlates to the diagnosis of metabolic syndrome in a subject wherein said subject is non-diabetic.
    Type: Grant
    Filed: March 8, 2013
    Date of Patent: December 31, 2019
    Assignee: SPHINGOTEC GMBH
    Inventors: Andreas Bergmann, Olle Melander
  • Patent number: 10501554
    Abstract: In certain embodiments, the present disclosure provides compositions and methods for treating tumors and cancer.
    Type: Grant
    Filed: August 27, 2015
    Date of Patent: December 10, 2019
    Assignee: Valerion Therapeutics, LLC
    Inventor: Dustin D. Armstrong
  • Patent number: 10501545
    Abstract: The present invention relates to anti-CLL-1 antibodies including anti-CLL-1 antibodies comprising a CLL-1 binding domain and a CD3 binding domain (e.g., anti-CLL-1/CD3 T cell dependent bispecific (TDB) antibody) and methods of using the same.
    Type: Grant
    Filed: June 14, 2016
    Date of Patent: December 10, 2019
    Assignee: Genentech, Inc.
    Inventors: Robert F. Kelley, Steven R. Leong, Wei-Ching Liang, Mary Mathieu, Andrew G. Polson, Bing Zheng, Xiaocheng Chen, Cecilia Pui Chi Chiu, Mark S. Dennis, Allen Ebens, Yan Wu
  • Patent number: 10485231
    Abstract: The present disclosure provides an anti-infective protector containing at least one anti-infective agent. The anti-infective protector provides for a range of benefits not appreciated in the prior art.
    Type: Grant
    Filed: March 12, 2018
    Date of Patent: November 26, 2019
    Assignee: Ansell Healthcare Products LLC
    Inventor: Debbie Wooley
  • Patent number: 10471098
    Abstract: Disclosed herein are compositions and methods for the treatment of liver metastases in a subject. The methods include hepatic arterial infusion (HAI) of chimeric antigen receptor modified T cells (CAR-T) which are highly specific for tumor antigens such as carcinoembryonic antigen (CEA). The HAI method is optimized to maximize exposure of the modified cells to the metastatic cells while minimizing exposure to healthy cells. The methods include co-administration of a second therapeutic agent, such as IL-2.
    Type: Grant
    Filed: April 14, 2016
    Date of Patent: November 12, 2019
    Assignee: PROSPECT CHARTERCARE RWMC, LLC
    Inventors: Steven C. Katz, Richard Junghans
  • Patent number: 10464890
    Abstract: In certain embodiments, the disclosure relates to methods of treating or preventing a PGAM1 mediated condition such as cancer or tumor growth comprising administering an effective amount of PGAM1 inhibitor, for example, an anthracene-9,10-dione derivative to a subject in need thereof. In certain embodiments, the disclosure relates to methods of treating or preventing cancer, such as lung cancer, head and neck cancer, and leukemia, comprising administering a therapeutically effective amount of a pharmaceutical composition comprising a compound disclosed herein or pharmaceutically acceptable salt to a subject in need thereof.
    Type: Grant
    Filed: December 19, 2017
    Date of Patent: November 5, 2019
    Assignee: Emory University
    Inventors: Jing Chen, Taro Hitosugi, Sumin Kang
  • Patent number: 10450260
    Abstract: This disclosure relates to compounds containing both an NO-releasing moiety and an H2S-releasing moiety and the use of such compounds in treating inflammatory diseases, including cancers.
    Type: Grant
    Filed: May 25, 2017
    Date of Patent: October 22, 2019
    Assignee: Research Foundation of The City University of New York
    Inventors: Khosrow Kashfi, Ravinder Kodela
  • Patent number: 10451625
    Abstract: Method and kits for detecting cancer, and in particular breast cancer, in a subject by measuring the levels of at least one of a series of biomarkers, as compared to a control sample lacking cancer. The expression of the biomarker either increases or decreases in samples from subjects with cancer, as compared to the expression level in subjects without cancer. The sample is optimally an ocular sample, such as an isolated tear sample or ocular wash, but can also be from saliva, or other bodily fluid. Kits can include a collection tube and protease inhibitors or protein stabilizers.
    Type: Grant
    Filed: October 9, 2015
    Date of Patent: October 22, 2019
    Assignee: Ascendant Diagnostics, LLC
    Inventors: Anna Daily, Lindsay Rutherford
  • Patent number: 10450356
    Abstract: The invention relates to a peptide having a length of no more than 100 amino acids and comprising at least 19 contiguous amino acids from the amino acid sequence of the human PRAME protein, wherein the peptide comprises at least one HLA class II epitope and at least one HLA class I epitope from the amino acid sequence of the human PRAME protein and to its use as such or in a composition as a medicament for the treatment and/or prevention of cancer.
    Type: Grant
    Filed: August 4, 2016
    Date of Patent: October 22, 2019
    Assignee: ACADEMISCH ZIEKENHUIS LEIDEN H.O.D.N. LUMC
    Inventors: Jan Kessler, Marieke Griffioen, Cornelis Johannes Maria Melief, Jan Wouter Drijfhout